Intel Chain

**UPDATE: GLP-1 Patent Landscape & Market Disruption** Two days ago, we examined how the GLP-1 receptor agonist class faces accelerating patent cliff dynamics, particularly as Novo Nordisk's Ozempic exclusivity windows narrow and biosimilar manufacturers position for 2026-2028 market entry. Recent regulatory filings indicate that mid-tier pharmaceutical firms are now advancing follow-on formulations targeting subcutaneous delivery improvements, suggesting the competitive intensity will concentrate on administration convenience rather than clinical efficacy differentiation. This patent compression, combined with mounting manufacturing capacity investments from emerging markets, underscores why early-mover advantages in this $100B+ class increasingly depend on distribution networks and patient loyalty rather than molecular innovation alone.